Published On: 5/13/2021

Crohn’s & Colitis 360 Publishes Target RWE Inflammatory Bowel Disease Data

Disorders of the gastrointestinal (GI) track disrupt the lives of millions of Americans every day. Chronic inflammation of the GI tract is also known as inflammatory bowel disease, or IBD. An estimated 3 million adults in the U.S. have been diagnosed with one of the two most common types of IBD: Crohn’s disease and ulcerative colitis.¹ Left untreated, IBD can lead to larger, more serious symptoms and complications. People with IBD are more likely to have other conditions including cardiovascular disease, respiratory disease, or liver disease, compared to people without an IBD diagnosis.¹

Sponsored by Target RWE, TARGET-IBD (NCT03251118) is an ongoing observational, longitudinal study that gathers and analyzes real-world data (RWD) on IBD patient treatment and care over several years. The study’s RWD includes important information from patients themselves called patient-reported outcome measures (PROs) and biospecimen samples, or blood samples. TARGET-IBD’s first published manuscript detailing methodology and initial results has been recently published in the Crohn’s and Colitis Foundation’s peer-reviewed journal Crohn’s & Colitis 360 (https://doi.org/10.1093/crocol/otab023).

“IBD is a common inflammatory health condition, but data from large observational studies among diverse patients in a real-world setting is lacking,” said Julie Mallory Crawford, MD, Senior Director of Scientific & Medical Affairs, Target RWE. “TARGET-IBD gives us insight into disease severity in different care settings, treatment patterns, and clinical outcomes. Research using this valuable data can influence the way that providers care for their IBD patients in real and meaningful ways.”

The TARGET-IBD initial study results included 1,343 IBD patients enrolled over the first year from 27 academic and community sites throughout the United States. Of these, 60.1% were diagnosed with Crohn’s disease and 38.9% were diagnosed with ulcerative colitis. Baseline PROs were provided by 48.7% of the cohort and 62.6% provided a biosample.

Learn more about TARGET-IBD here.

¹Centers for Disease Control and Prevention: https://www.cdc.gov/ibd/data-statistics.htm